UAE Walid Kattouha, Head of the Middle East Cluster of Novartis, speaks about why local knowledge is key to the company’s success, what have been and continues to be the major challenges for the company, and what the future looks like. You are the leading pharmaceutical company in the Middle…
UAE Jan Van der Goten, GCC Managing Director of Janssen UAE, talks about his experience at Janssen GCC as regional manager, how collaboration with other companies in the industry will bring about better results for the issue of diabetes, and why this may be harder to accomplish than expected. You…
UAE Paolo Carli, Head of Middle East, KSA & Egypt for Merck Serono, speaks about the regions most pressing health issues—hypertension and diabetes— and how he thinks that collaboration of the industry with the government and educational institutes will help overcome this problem before it’s too late. Our approach to…
Collaboration Paolo Carli, Head of Middle East, KSA & Egypt for Merck Serono, speaks about the regions most pressing health issues—hypertension and diabetes— and how he thinks that collaboration of the industry with the government and educational institutes will help overcome this problem before it’s too late. What are some of…
MNCs Lloyd D. Balajadia, Executive Director of Lloyd Laboratories talks about the advantages and disadvantages of the recent spike in generic medicine within the Philippine market, why despite a contract manufacturer being good for Lloyd Laboratories, it would be but bad for the job market and business opportunities in the Philippines,…
diabetes Christine Marie D. Rosal, Country Manager of Novo Nordisk Pharmaceuticals (Philippines) gives a startling image of the current state of diabetes in the Philippines, the major reasons behind the soaring rates of diabetes and what the government along with companies such as Novo Nordisk can do to prevent a worsening…
R&D Dr. Olsson Birgersson, Medical Director of Roche Sweden argues the importance of developing clinical research within Sweden, why the Swedish healthcare system is no longer the forerunner in Europe that it once was, and Roche’s intentions of further strengthening personalized healthcare products while adapting to the needs of their costumers.…
Generics Dr. Chen, you joined US-based Anchen Pharmaceuticals in 2009 to help the company form a spin-off in Taiwan. Why did a US-based company look to establish itself in Taiwan, and then export back to the US? In my view, the US is not a very attractive environment for a company…
Generics In the first part of this two-part interview, the Chairman of TTY Biopharm considers the success of his long-term strategy to streamline TTY’s portfolio and focus on the company’s strengths, and talks about the opportunities in Asia for companies that have followed a similar path to TTY. To read the…
canada foundation for innovation Tell us about the Canada Foundation for Innovation (CFI) – where does Canada fit on the world stage of innovation and how are you ensuring Canada stands out as a top destination for innovation today? The Canada Foundation for Innovation (CFI) funds research infrastructure. The organization was created in…
Department of Industry Would you outline the commitment of the Ministry to foster a positive business environment for the Australian pharmaceutical industry to prosper? Issues faced by the pharmaceutical industry are not unlike those in many other industries and the high value of our dollar has brought a sharp focus to industry productivity…
See our Cookie Privacy Policy Here
